The performance of PRIOR was compared with that of other available methods by counting the number of test cases for which a near-native solution is ranked within the 20 best-ranked conformations. We compared these values for the cases common to a given method's test set and PRIOR's test set on the one hand, and for each method's complete test set on the other hand (Figure 1) . When comparing results obtained on the same test sets or on complete sets, PRIOR gives the highest values. Percentages obtained by RosettaDock are surprisingly low. However, it should be reminded that, unlike all other methods, RosettaDock does not rank a large number of conformations, but rather optimizes just one given conformation.
, FTDock+f (FTDock with residue conservation information) [7] , AspDock [8] , LZerD [9] , GEODock [8] , CS (Context shapes) [9] , PatchDock [9] and FTDock [7] . In -arrestin 1, residue R307 was shown to be crucial for the interaction with Raf, whereas equivalent residue K308 in -arrestin 2 does not a↵ect binding. In our models, residue R307 does make an interaction with residue K84 in Raf. In -arrestin 2, side chain of residue K308 points upward and thus does not make any interaction with Raf. A: the positions of P120 and P121 belonging to the c-Src epitope on -arrestin are slightly a↵ected by the activation, residue P91 is much closer to c-Src in the active conformation. B: residue K307, which is known to be important for the interaction with Raf is not present in the active -arrestin structure. However, from the position of residue 308, it can be deduced that K307 will be closer to the predicted position of Raf in the active conformation than in the inactive one. C: The conformation of the Mek epitope on -arrestin is slightly a↵ected by the activation. D: the loop containing residue K295 undergoes important conformational changes upon activation, which brings it much closer to the predicted position of ERK1, allowing direct interactions. It should also be noted that the C-tail of the receptor is predicted to come in direct interaction with ERK1. Figure 7 : Detail of the interactions between the active -arrestin, the V2R peptide and ERK. -arrestin is shown in grey, ERK in dark red, and the V2R peptide is shown as spheres. On the left side, three independent experiments comparing the e↵ects of control, Raf and barr1 peptides were blotted and sequentially probed with anti--arrestin (upper blots) and anti-GST (lower blots) antibodies. On the right side are shown three independent experiments comparing the e↵ect of control peptide versus no peptide on the direct interaction of -arrestin1 with GST-Raf1-RBD. All these blots were quantified and normalized as presented in figure 5A . Figure 10 : Experimental validation of the predicted -arrestin1-ERK2 interaction sites. Equal amounts of GST-ERK2 fusion protein were incubated with 25 ng of -arrestin1 and with or without 0.5 mM of the indicated peptide. Three independent experiments were simultaneously blotted and sequentially probed with anti--arrestin (upper blot) and anti-ERK (lower blot) antibodies. The arrow shows the -arrestin signal that remained after the blot was stripped and reprobed with anti-ERK antibody. These blots were quantified and normalized as presented in figure 5B .
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